Sugi Predict

Sugi Predict / Compounds / SCHEMBL148044

SCHEMBL148044

SCHEMBL148044

Cc1ccc(Cl)c(Cc2cc3ccc(OC(F)F)cc3s2)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC5A2 P31639 3/20 0.34
▸ HTR2A P28223 2/20 0.33
▸ SLC6A4 P31645 2/20 0.33
▸ KCNH2 Q12809 2/20 0.33
▸ OPRM1 P35372 1/20 0.32
▸ LMNA P02545 3/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ KCNJ5 P48544 1/20 0.32
▸ KCNJ3 P48549 1/20 0.32
▸ SLC5A1 P13866 2/20 0.32
▸ CRHR1 P34998 1/20 0.31
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ USP2 O75604 1/20 0.31
▸ AGTR1 P30556 1/20 0.31
▸ HDAC3 O15379 1/20 0.31
▸ HDAC4 P56524 1/20 0.31
▸ HDAC1 Q13547 1/20 0.31
▸ HDAC7 Q8WUI4 1/20 0.31
▸ HDAC2 Q92769 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL147498 0.88 ALDH1A1 (0.34) LMNAMEN1KMT2ASMN1; SMN2HDAC3
SCHEMBL156018 0.86 SLC5A2 (0.34) SLC5A2HTR2ASLC6A4KCNH2KCNJ5
SCHEMBL22782129 0.84 SLC5A2 (0.41) SLC5A2HTR2ASLC6A4KCNH2OPRM1
SCHEMBL152700 0.77 KMT2A (0.31) MEN1KMT2AALDH1A1MAPTPTGER4
SCHEMBL148151 0.77 SLC5A2 (0.37) SLC5A2HTR2ASLC6A4KCNH2LMNA
SCHEMBL154569 0.77 SLC6A4 (0.36) SLC5A2HTR2ASLC6A4KCNH2LMNA
SCHEMBL14278454 0.76 SLC5A2 (0.53) SLC5A2SLC5A1
SCHEMBL147487 0.74 BACE1 (0.39) SLC5A2KCNJ5KCNJ3SLC5A1SMN1; SMN2
SCHEMBL148134 0.74 KMT2A (0.44) SLC5A2HTR2ASLC6A4KCNH2KMT2A
SCHEMBL144731 0.74 SLC6A4 (0.37) SLC5A2HTR2ASLC6A4KCNH2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1651658-B2 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER MITSUBISHI TANABE PHARMA CORP (JP) 2020-08-12 — — EP disclosed
EP-3251679-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER Mitsubishi Tanabe Pharma Corporation (JP) 2017-12-06 — — EP disclosed
EP-2896397-B1 Novel compounds having inhibitory activity against sodium-dependant glucose transporter MITSUBISHI TANABE PHARMA CORP (JP) 2017-09-06 — — EP disclosed
US-20160108078-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-04-21 — — US disclosed
US-20160108078-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-04-21 — — US disclosed
US-20140296506-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-10-02 — — US disclosed
US-20140296506-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-10-02 — — US disclosed
US-8785403-B2 Glucopyranoside compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-07-22 — — US disclosed
US-8785403-B2 Glucopyranoside compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-07-22 — — US disclosed
US-20120258913-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-10-11 — — US disclosed
US-8222219-B2 Glucopyranoside compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-07-17 — — US disclosed
US-8222219-B2 Glucopyranoside compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-07-17 — — US disclosed
US-8202984-B2 Glucopyranoside compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-06-19 — — US disclosed
US-8202984-B2 Glucopyranoside compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-06-19 — — US disclosed
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-08 — — US disclosed
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-08 — — US disclosed
US-7943788-B2 Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-17 — — US disclosed
US-7943788-B2 Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-17 — — US disclosed
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-05 — — US disclosed
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 SLC5A2 5/4885HTR2A 3104/4885SLC6A4 1396/4885
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 SLC5A2 5/4885HTR2A 3104/4885SLC6A4 1396/4885
US-20120258913-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 SLC5A2 5/4885HTR2A 3104/4885SLC6A4 1396/4885
US-20160108078-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 SLC5A2 5/4885HTR2A 3104/4885SLC6A4 1396/4885
US-20140296506-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 SLC5A2 5/4885HTR2A 3104/4885SLC6A4 1396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.